Semaglutide Effect on Kidney, Cardiovascular, and Mortality Outcomes in Racial and Ethnic Groups
Clinical Journal of the American Society of Nephrology · 18.11.2026
DOI: 10.2215/cjn.0000001242 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Journal of the American Society of Nephrology, online erschienen am 18.11.2026. Verfasst von Carlos Campos und 10 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Potential variation in semaglutide treatment response across racial and ethnic groups of people with chronic kidney disease and type 2 diabetes has not been assessed. In a post hoc analysis of the international FLOW randomized controlled clinical trial, we assessed the efficacy of once-weekly subcutaneous semaglutide 1.0 mg vs placebo on kidney and cardiovascular outcomes in racial and ethnic subgroups.
Methods
Using FLOW trial data, we compared semaglutide 1.0 mg vs placebo (in addition to the standard of care) on the primary kidney outcome (onset of kidney failure, ≥50% reduction in estimate glomerular filtration rate [eGFR] from baseline sustained for ≥28 days, or death from kidney-related or cardiovascular causes) and three confirmatory secondary outcomes (annual change [total slope] in eGFR, major adverse cardiovascular events [MACE], and all-cause death) between Black/African American and non-Black/African American participants and between Hispanic/Latino and non-Hispanic/Latino participants. Cox proportional hazards models were used to compare semaglutide 1.0 mg vs placebo groups on the occurrence of the primary kidney outcome, MACE, and all-cause death. Random-effects linear regression models were used to compare groups on the change in eGFR. Models included interaction terms for treatment by race or ethnicity.
Results
Of 3,533 total participants in the FLOW trial, 3,454 had race data available (Black/African American, n=160; non-Black/African American, n=3,294), and 3,388 had ethnicity data available (Hispanic/Latino, n=556; non-Hispanic Latino, n=2,832). Over a median 3.4 years of follow-up, the effect of semaglutide on the primary kidney outcome, MACE, all-cause death, and annual change in eGFR did not statistically significantly differ between Black/African American and non-Black/African American participants or between Hispanic/Latino and non-Hispanic/Latino participants (all interaction P-values >0.05).
Conclusion
In this post hoc exploratory analysis of the FLOW trial, there was no statistical evidence that the efficacy of semaglutide treatment on kidney and cardiovascular outcomes differed by race or ethnicity.
Zitieren
APA
Campos, C., Pratley, R., Mehanna, S., Swift, C., Rasmussen, S., Rossing, P., Tuttle, K., Mahaffey, K. W., Busch, R., Charytan, D. M., & Mende, C. (2026). Semaglutide Effect on Kidney, Cardiovascular, and Mortality Outcomes in Racial and Ethnic Groups. Clinical Journal of the American Society of Nephrology. https://doi.org/10.2215/cjn.0000001242
Vancouver
Campos C, Pratley R, Mehanna S, Swift C, Rasmussen S, Rossing P, et al. Semaglutide Effect on Kidney, Cardiovascular, and Mortality Outcomes in Racial and Ethnic Groups. Clinical Journal of the American Society of Nephrology. 2026. doi:10.2215/cjn.0000001242
BibTeX
@article{Campos2026,
author = {Campos, Carlos and Pratley, Richard and Mehanna, Sherif and Swift, Caroline and Rasmussen, Søren and Rossing, Peter and Tuttle, Katherine and Mahaffey, Kenneth W. and Busch, Robert and Charytan, David M. and Mende, Christian},
title = {Semaglutide Effect on Kidney, Cardiovascular, and Mortality Outcomes in Racial and Ethnic Groups},
journal = {Clinical Journal of the American Society of Nephrology},
year = {2026},
doi = {10.2215/cjn.0000001242}
}
EUVIMED